Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Blank Check IPOs (SPACS) -- Ignore unavailable to you. Want to Upgrade?

To: debrahaugen who wrote (1137)	8/2/2007 10:46:51 PM
From: Rollcast...	Respond to of 3862

Weird action in both the HAQ common and Wts. Probably some serious differences between management and Millenium Partners and Bear Stearns Innov Fund with Maxim thrown into really screw things up. If they do manage to screw the deal I think they all look bad and understand this... thus the 2 more days additional time to lobby and negotiate. Like looking bad matters to Millenium Partners....

To: debrahaugen who wrote (1137)	8/3/2007 1:54:52 PM
From: Rollcast...	Respond to of 3862

HAQ deal approved. HAQ wts up 11 cents. Healthcare Acquisition Corp. and PharmAthene Receive Stockholder Approval for Their Merger Friday August 3, 1:08 pm ET DES MOINES, Iowa & ANNAPOLIS, Md.--(BUSINESS WIRE)--Healthcare Acquisition Corp. (AMEX:HAQ - News), a publicly-traded special purpose acquisition company, and PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures against biological and chemical threats, today announced that the stockholders of HAQ had approved the proposed merger of HAQ and PharmAthene. In addition, holders of fewer than 20% of the shares of HAQ's common stock issued in its initial public offering exercised their right to convert shares into a pro rata portion of the proceeds of HAQ's IPO which were held in a trust account. HAQ stockholders also approved certain merger related proposals, such as amendment to HAQ's charter to, among other things, change its name to "PharmAthene, Inc." and to approve the 2007 Incentive Plan. The merger will be completed later today. ADVERTISEMENT HAQ and PharmAthene further announced that certain of the officers, directors and current stockholders of HAQ had purchased 250,000 additional shares of HAQ common stock and funds associated with Healthcare Ventures and funds associated with MPM Capital, which are current stockholders of PharmAthene, had each purchased 125,000 shares of HAQ common stock prior to the Special Meeting of Stockholders. John Pappajohn, HAQ's Chairman who will continue as Chairman of the combined company, noted that, "The purchases by management and existing stockholders demonstrated their continued endorsement of the merger. We are pleased that our stockholders have recognized the potential benefits associated with the merger by their approval of the transaction. We strongly believe PharmAthene's business model represents a compelling value proposition." David P. Wright, Chief Executive Officer of PharmAthene who will remain in such position with the combined company, commented, "Our merger with HAQ will allow the combined company the financial flexibility to build a stronger financial foundation with enhanced access to capital with which to grow our business." About PharmAthene, Inc. PharmAthene was formed as a result of a merger with Healthcare Acquisition Corp. PharmAthene is a biodefense company developing and commercializing medical countermeasures against biological and chemical threats. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia® for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit www.PharmAthene.com. Healthcare Acquisition Corp. was a blank check company that was formed for the specific purpose of consummating a business combination. Forward Looking Statement Disclosure This press release contains certain "forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are not historical facts but are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of PharmAthene. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to PharmAthene or any of their collaborators cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, (b) PharmAthene or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) PharmAthene may not be able to obtain anticipated funding for its development projects or other needed funding, (d) PharmAthene may not be able to secure funding from anticipated government contracts and grants, and (e) PharmAthene may not be able to secure or enforce adequate legal protection, including patent protection, for their products. The information contained in this press release should be read in light of such risks. The Company does not assume any obligation to update the information contained in this press release. Contact: PharmAthene, Inc. Stacey Jurchison, 410-269-2610 jurchisons@pharmathene.com

To: debrahaugen who wrote (1137)	8/6/2007 4:09:33 PM
From: Rollcast...	Read Replies (2) \| Respond to of 3862

Trading halted on HAQ... Healthcare Acquisition Corp. and PharmAthene Reconfirms Receipt of Stockholder Approval for Their Merger Friday August 3, 4:02 pm ET DES MOINES, Iowa & ANNAPOLIS, Md.--(BUSINESS WIRE)--Healthcare Acquisition Corp. (AMEX:HAQ - News), a publicly-traded special purpose acquisition company, and PharmAthene, Inc., a biodefense company developing and commercializing medical countermeasures against biological and chemical threats, today announced that the trading halt in the stock and warrants of the Company was the result of inaccurate information received after its stockholders meeting from its transfer agent. The trading was halted while the parties and the transfer agent for the Company investigated the accuracy of the previously reported vote. ADVERTISEMENT About PharmAthene, Inc. PharmAthene was formed as a result of a merger with Healthcare Acquisition Corp. PharmAthene is a biodefense company developing and commercializing medical countermeasures against biological and chemical threats. PharmAthene's lead programs include Valortim(TM) for the prevention and treatment of anthrax infection and Protexia® for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents. For more information on PharmAthene, please visit www.PharmAthene.com. Healthcare Acquisition Corp. was a blank check company that was formed for the specific purpose of consummating a business combination. Forward Looking Statement Disclosure This press release contains certain "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the efficacy of potential products, the timelines for bringing such products to market and the availability of funding sources for continued development of such products. Forward-looking statements are not historical facts but are based on management's estimates, assumptions and projections, and are subject to uncertainties, many of which are beyond the control of PharmAthene. Actual results may differ materially from those anticipated in any forward-looking statement. Factors that may cause such differences include the risks that (a) potential products that appear promising to PharmAthene or any of their collaborators cannot be shown to be efficacious or safe in subsequent preclinical or clinical trials, (b) PharmAthene or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products, (c) PharmAthene may not be able to obtain anticipated funding for its development projects or other needed funding, (d) PharmAthene may not be able to secure funding from anticipated government contracts and grants, and (e) PharmAthene may not be able to secure or enforce adequate legal protection, including patent protection, for their products. The information contained in this press release should be read in light of such risks. The Company does not assume any obligation to update the information contained in this press release. Contact: PharmAthene, Inc. Stacey Jurchison, 410-269-2610 jurchisons@pharmathene.com Source: Healthcare Acquisition Corp. biz.yahoo.com